Compare FTAI Aviation Ltd (FTAI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs TransMedics Group Inc — how do they compare? FTAI Aviation Ltd trades at $169.46 (market cap $17.57B), while TransMedics Group Inc trades at $78.41 (market cap $2.74B). The key difference: FTAI Aviation Ltd is far larger — about 6.4× TransMedics Group Inc's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 23 Days and TransMedics Group Inc for 24 Days on average.
| FTAI | TMDX | |
|---|---|---|
Market Cap | $17.57B | $2.74B |
Volume | 1,905,014 | 949,331 |
Sector | Industrials | Health |
52-Week High | $310.04 | $150.42 |
52-Week Low | $152.80 | $61.99 |
Typical Hold Time | 23 Days | 24 Days |
Enterprise Value | $20.69B | $3.13B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
